Maxim Group Maintains Buy on Actinium Pharma, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy maintains a Buy rating on Actinium Pharma (AMEX:ATNM) but lowers the price target from $30 to $5.

August 06, 2024 | 2:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Maxim Group analyst Jason McCarthy maintains a Buy rating on Actinium Pharma but significantly lowers the price target from $30 to $5.
The significant reduction in the price target from $30 to $5, despite maintaining a Buy rating, suggests a negative outlook on the stock's short-term performance. This could lead to a decline in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100